Kezar Life Sciences Inc (KZR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kezar Life Sciences Inc (KZR) has a cash flow conversion efficiency ratio of -0.114x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.45 Million) by net assets ($65.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KZR net asset quality index to measure how much of total assets are equity-financed.
Kezar Life Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Kezar Life Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore KZR cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Kezar Life Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kezar Life Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zeta Network Group
NASDAQ:ZNB
|
0.014x |
|
Colefax Group
LSE:CFX
|
0.297x |
|
Companhia Tecidos Santanense Ltda
SA:CTSA3
|
0.074x |
|
Paranovus Entertainment Technology Ltd.
NASDAQ:PAVS
|
-0.006x |
|
Alveen
PA:MLALV
|
N/A |
|
Baosheng Media Group Holdings Ltd
NASDAQ:BAOS
|
-0.522x |
|
CJ Seafood Corp. Pfd. Series 1
KO:011155
|
-0.045x |
|
Ribbon Acquisition Corp Rights
NASDAQ:RIBBR
|
N/A |
Annual Cash Flow Conversion Efficiency for Kezar Life Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kezar Life Sciences Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see KZR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $70.07 Million | $-51.78 Million | -0.739x | -16.41% |
| 2024-12-31 | $116.92 Million | $-74.21 Million | -0.635x | -45.83% |
| 2023-12-31 | $187.57 Million | $-81.64 Million | -0.435x | -99.62% |
| 2022-12-31 | $269.87 Million | $-58.85 Million | -0.218x | -1.16% |
| 2021-12-31 | $196.88 Million | $-42.44 Million | -0.216x | +17.76% |
| 2020-12-31 | $140.98 Million | $-36.95 Million | -0.262x | +31.54% |
| 2019-12-31 | $78.05 Million | $-29.88 Million | -0.383x | -100.31% |
| 2018-12-31 | $108.80 Million | $-20.79 Million | -0.191x | -160.54% |
| 2017-12-31 | $-25.69 Million | $-8.11 Million | 0.316x | -43.63% |
| 2016-12-31 | $-17.43 Million | $-9.76 Million | 0.560x | -- |
About Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyo… Read more